Natera and TransCode announce Phase 2a collaboration: Natera stock pre-market at EUR 354.00
Published on 10/14/2026 at 08:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTrial collaboration and trading outlook
- Natera and TransCode announced a colorectal cancer collaboration on October 13, 2026.
- Natera stock was at EUR 354.00 pre-market at Lang & Schwarz on October 14, 2026, at 8:21 a.m. CEST.
- The TransCode study is a Phase 2a trial registered under NCT05868226.
In a Business Wire release dated October 13, 2026, Natera, Inc. and TransCode Therapeutics announced a strategic collaboration to support enrollment in TransCode’s Phase 2a trial of TTX-MC138 in colorectal cancer.
Pre-market trading
Natera stock was at EUR 354.00 at Lang & Schwarz on October 14, 2026, at 8:21 a.m. CEST, ahead of the Xetra open. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Natera stock.
Today’s company focus
The dated company announcement for the outlook is from October 13, 2026. The collaboration supports a Phase 2a trial in colorectal cancer. The study is registered under NCT05868226.
Trial collaboration
Under the agreement, TransCode will use Natera’s Signatera test to identify patients who remain positive for molecular residual disease after curative-intent therapy and have no radiographic evidence of disease. The companies said the collaboration is intended to improve patient identification and streamline enrollment. The study is being conducted by Quantum Leap Healthcare Collaborative within its PRE-I-SPY program. These details were provided in the Business Wire release.
Market context: Market report S&P 500.
